Survival and causes of death in patients with alpha and beta-thalassemia in Northern Thailand

Ann Med. 2024 Dec;56(1):2338246. doi: 10.1080/07853890.2024.2338246. Epub 2024 Apr 11.

Abstract

Background: Thalassemia is the most prevalent hereditary anaemia worldwide. Severe forms of thalassemia can lead to reduced life expectancy due to disease-related complications.

Objectives: To investigate the survival of thalassemia patients across varying disease severity, causes of death and related clinical factors.

Patients and methods: We conducted a retrospective review of thalassemia patients who received medical care at Chiang Mai University Hospital. The analysis focused on survival outcomes, and potential associations between clinical factors and patient survival.

Results: A total of 789 patients were included in our study cohort. Among them, 38.1% had Hb H disease, 35.4% had Hb E/beta-thalassemia and 26.5% had beta-thalassemia major. Half of the patients (50.1%) required regular transfusions. Sixty-five patients (8.2%) had deceased. The predominant causes of mortality were infection-related (36.9%) and cardiac complications (27.7%). Transfusion-dependent thalassemia (TDT) (adjusted HR 3.68, 95% CI 1.39-9.72, p = 0.008) and a mean serum ferritin level ≥3000 ng/mL (adjusted HR 4.18, 95% CI 2.20-7.92, p < 0.001) were independently associated with poorer survival.

Conclusions: Our study highlights the primary contributors to mortality in patients with thalassemia as infection-related issues and cardiac complications. It also underscores the significant impact of TDT and elevated serum ferritin levels on the survival of thalassemia patients.

Keywords: Cardiac complications; infection; iron overload; mortality; survival; thalassemia.

MeSH terms

  • Cause of Death
  • Heart Diseases*
  • Humans
  • Iron Overload* / etiology
  • Risk Factors
  • Thailand / epidemiology
  • Thalassemia* / complications
  • beta-Thalassemia* / complications
  • beta-Thalassemia* / epidemiology
  • beta-Thalassemia* / therapy

Grants and funding

No funding was received.